Top Vaccine Markets by Country: Leaders and Fast Growers

Top Vaccine Markets by Country: Leaders and Fast Growers

The United States is the largest vaccine market in the world by a wide margin. It generated USD 18.67 billion in 2025, or 22.80% of global revenue, according to Cognitive Market Research and Consulting’s Vaccine Market Analysis 2026. China follows at USD 7.30 billion. The fastest growth among the top markets, however, is not in the biggest economies. India is projected to grow at 7.267% a year from 2025 to 2033, the quickest rate of any country in the top eight. This article ranks the leading countries, explains where growth is coming from, and sets out what the numbers mean for manufacturers and buyers.

Which Countries Have the Largest Vaccine Markets?

The 2025 ranking is led by the United States, followed by China, Japan, Germany, India, the United Kingdom, Canada and France. Together these eight markets account for roughly 56% of global vaccine revenue, a figure we calculated from the report’s stated shares.

The US is well ahead of the field. Its USD 18.67 billion is more than twice China’s USD 7.30 billion. Japan (USD 4.32 billion) and Germany (USD 4.16 billion) sit close together in third and fourth place. India, at USD 3.37 billion, edges out the UK at USD 3.25 billion. South Korea (USD 2.23 billion) and Spain (USD 2.14 billion) follow just outside the top eight.

How Concentrated Is Vaccine Revenue Among the Top Countries?

Revenue is concentrated in a few places. The four largest markets, the US, China, Japan and Germany, hold 42.06% of global revenue between them. The US alone accounts for 22.80%, nearly a quarter of world vaccine spending. That gives the American market an outsized influence on global pricing and product launches. A change in US payer policy or procurement can move the global total far more than a comparable shift in a smaller country.

Europe is more spread out. Germany, the UK, France, Spain and Italy together hold 17.19% of global revenue, with no single country above 5.08%.

Which Top Markets Are Growing Fastest?

Size and growth tell different stories. The report’s country table gives a compound annual growth rate (CAGR) for each market from 2025 to 2033, against a global rate of 5.572%. India leads the top eight at 7.267%, followed by China at 6.529% and Germany at 5.927%. Japan, Canada and the UK also grow faster than the global average. The US, at 4.848%, and France, at 4.573%, grow more slowly.

The result is a split. The largest market is growing below the average pace, while several mid-sized markets are compounding faster. For a manufacturer, the US is still where most of the revenue sits. For a company looking for the next leg of growth, India and China stand out.

India: Closing the Gap Among the Top Five

India is the clearest case of a smaller market closing the distance. Its revenue rose from USD 2.55 billion in 2021 to USD 3.37 billion in 2025, and the report projects USD 5.91 billion by 2033. Japan remains ahead, but the gap narrows from USD 0.95 billion in 2025 to USD 0.80 billion in 2033.

Recent Indian market data points the same way. A BioSpectrum review in February 2026 reported 17% year-on-year value growth for India’s vaccine segment, driven by adult immunisation and rising rabies and influenza uptake. Pharmarack’s tracking of the Indian Pharmaceutical Market showed the vaccine group posting 24.4% value growth and 32.3% unit growth in January 2026. These are short-term market signals, not the report’s forecast, but they support the long-term trend.

What Could the Top Countries Look Like by 2033?

Those growth rates reshape the ranking only slightly. By 2033 the US is still the largest market at USD 27.27 billion, and China rises to USD 12.10 billion. Japan (USD 6.71 billion) and Germany (USD 6.60 billion) stay close together, with India at USD 5.91 billion ahead of the UK at USD 5.00 billion.

In absolute terms, the US adds the most: USD 8.60 billion between 2025 and 2033, against China’s USD 4.80 billion. Japan and India add similar amounts, USD 2.39 billion and USD 2.54 billion, but from very different bases. The US’s advantage is scale. India’s is pace. The US share of global revenue slips from 22.80% in 2025 to about 21.6% in 2033, a figure we calculated from the report’s country and global forecasts.

What Drives Demand in the Largest Markets?

Each top market has its own demand profile. The report’s regional findings show where buyers are different.

In the US, high healthcare spending and widespread insurance coverage support demand, and major pharmaceutical and biotech firms are based there. Buyers also face constant pricing pressure from payers, and vaccine hesitancy and misinformation affect uptake.

In China, a large population and rising government investment in public health drive demand. Local manufacturers are expanding production of cost-effective vaccines for national programmes, which can change pricing for imported products.

In Europe, which includes Germany, the UK, France and Spain, national immunisation programmes and high coverage anchor demand. Pricing is more complex: value-based pricing and health technology assessment are gaining ground, and reimbursement rules vary by country. An ageing population is pushing demand for pneumonia and shingles vaccines.

In India, a large population and birth cohorts sustain volume, while adult immunisation and private-market participation are growing.

What Does Germany’s Stockpile Drawdown Signal?

Germany is the fourth-largest market, with USD 4.16 billion in 2025, 5.08% of global revenue, and a projected CAGR of 5.927%. A development in early August 2026 shows how quickly near-term demand can shift. BioNTech cut its 2026 revenue guidance to €1.6–1.9 billion from €2.0–2.3 billion on 4 August, citing weaker COVID-19 vaccine demand and the drawdown of existing vaccine stockpiles in Germany. Second-quarter revenue fell to €105.6 million from €260.8 million a year earlier.

The lesson for the wider market is that government reserves can pull purchases forward and then pause them. A forecast to 2033 describes the long-run trend, but a single season can swing a company’s revenue. Manufacturers should treat Germany’s 2025 base as a planning anchor, not as a guide to any single quarter.

How We Researched These Country Figures

Country values come from Cognitive Market Research and Consulting’s Vaccine Market Analysis 2026, with data updated in August 2026. The report’s research framework is 70% primary and 30% secondary, with 54 expert interviews and more than 10,400 validated data points. Country values are in USD billion.

Shares are as stated in the report. Combined shares, the 2033 share calculation, and the India gap are our own calculations from the reported values, and the text says so where they appear. The report’s Africa sub-country rows are locked in the free preview, so they are not discussed here.

What Should Manufacturers and Buyers Do With These Rankings?

Different goals point to different markets:

Scale: The US remains the largest revenue pool, where payer pricing and approval timelines shape returns.
Growth: India and China combine the fastest growth rates with large populations and expanding local production.
Planning: Germany’s stockpile experience shows why government purchasing can move sharply in a single year, and why reserve planning matters for suppliers.

Country rankings show where vaccine revenue sits today. Growth rates show where it may be heading. For the largest markets, those two signals point in different directions. To see the full country tables, the forecast for each market, and the segment data behind them,request a free sample of the Vaccine Market Analysis 2026 report. Manufacturers weighing market entry or portfolio choices can speak to a vaccine market analyst. Related reports include influenza vaccine market report and mRNA vaccine market report.